A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED
NCT ID: NCT03529331
Last Updated: 2019-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2019-09-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet)
NCT03088826
Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge
NCT01402375
IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients
NCT03553498
Acetaminophen IV vs Hydromorphone IV in the ED
NCT03107481
Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
NCT03521102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is to evaluate and compare rates of recurrent use (surrogate for abuse liability and likeability) of Morphine Sulfate Immediate Release, Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at discharge from the ED (by comparing a percentage of patients in each group at 1 month, 3 months and 6 months that are still using the same opioid analgesics for presumably non-medical use.
Objective and Hypothesis:
The outcome of the study is to evaluate and compare the rates of recurrent use of prescribed opioids at discharge from the ED by comparing a percentage of patients in each group at 1 month, 3 months and 6 months that are still using the same opioid analgesics for presumably non-medical use that will be used as a surrogate for comparison of abuse liability and likeability. Our goal is to prove that MSIR will have the lowest recurrent use rates at specified time periods than Percocet and Vicodin and that MSIR should be considered as the opioid of choice at discharge from the ED. Our hypothesis is that MSIR is associated with lower number of patients with recurrent use at specified time periods than Percocet and Vicodin due to the lesser abuse liability and likeability.
Methodology:
This is a prospective randomized, clinical trial comparing recurrent use of Morphine Sulfate Immediate Release (MSIR), Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at discharge from the ED for opioid-naive adult patients presenting with moderate-to-severe pain. At discharge, patients will be randomized to receive either 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days, 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days, or 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days. At 1 month, 3 months, and 6 months patients' prescription's history will be accessed by using the DoctorFirst Drug Database to determine the recurrent use that will serve as a surrogate marker of likeability and abuse liability of each prescribed opioid.
Statistical Analyses:
The nominal variables will be presented as percentages with confidence intervals (CIs), and continuous variables will be presented as means with SDs, or medians with interquartile ranges when appropriate. The odds ratios of recurrent use will be compared with logistic regression to adjust for age, sex, race, chief complaint, and opioid prescription filling. In addition, to test for proportional difference with respect to recurrent opioid use, we will use a Pearson Chi-square test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Morphine Sulfate Immediate Release
ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
Morphine Sulfate Immediate Release
15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
Oxycodone/Acetaminophen (Percocet),
ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
Oxycodone/Acetaminophen
5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
Hydrocodone/Acetaminophen (Vicodin)
ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
Hydrocodone/Acetaminophen
5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Morphine Sulfate Immediate Release
15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
Oxycodone/Acetaminophen
5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
Hydrocodone/Acetaminophen
5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 and older
* acute to moderate to severe pain
* requires oral opioid medications at ED discharge.
Exclusion Criteria
* patients with history of substance abuse
* patients with opioid use disorder,
* patients simultaneously taking antidepressants, benzodiazepines and other sedative-hypnotics,
* and allergies to any of the medications.
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Antonios Likourezos
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonios Likourezos
Research Manager
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sergey Motov, MD
Role: PRINCIPAL_INVESTIGATOR
Maimonides Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maimonides Medical Center
Brooklyn, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-03-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.